多发性骨髓瘤免疫治疗的现状与挑战  

Current status and challenges of immunotherapy for multiple myeloma

作　　者：侯健 王君颖 HOU Jian;WANG Jun-ying(Department of Hematology,Renji Hospital,School of Medicine,Shanghai Jiao Tong University,Shanghai 200127,China)

机构地区：[1]上海交通大学医学院附属仁济医院血液科,上海200127

出　　处：《现代免疫学》2025年第1期1-6,共6页Current Immunology

基　　金：国家自然科学基金(81974006)。

摘　　要：就现阶段而言,多发性骨髓瘤(multiple myeloma,MM)是一种不可治愈的疾病。近年来,以CD38单克隆抗体为代表的免疫治疗药物被广泛应用于临床,这显著延长了MM患者的生存期。与此同时,嵌合抗原受体(chimeric antigen receptor,CAR)-T细胞、抗体药物偶联物(antibody-drug conjugate,ADC)、双特异性抗体(bispecific antibody,BsAb)等多种高效、新型的免疫治疗制剂不断涌现,免疫治疗正在改变MM的治疗格局。该文就目前MM免疫治疗领域的发展现状及其面临的挑战进行阐述,同时对免疫治疗未来的发展方向提出思考和建议,旨在为MM诊治研究提供参考。At present,multiple myeloma(MM)remains an incurable disease.In recent years,immunotherapeutic drugs,represented by CD38 monoclonal antibody,have been widely used in the clinical practice and significantly prolonged the survival of MM patients.Meanwhile,a variety of highly effective novel immunotherapeutic agents such as chimeric antigen receptor(CAR)-T cell,antibody-drug conjugate(ADC),and bispecific antibody(BsAb)are continuously emerging,reshaping the treatment landscape of MM.This review summarizes the current development and challenges in the field of immunotherapy for MM,while also offering reflections and suggestions on the future direction of immunotherapy,for providing the reference in the field of MM diagnosis and treatment research.

关 键 词：多发性骨髓瘤 免疫治疗 单克隆抗体 嵌合抗原受体-T细胞疗法 双特异性抗体 抗体药物偶联物 

分 类 号：R733.3[医药卫生—肿瘤] R457.2[医药卫生—临床医学]